DexTech announces that OsteoDex´ (ODX) pre-clinical results regarding the effect on multiple myeloma (MM) are so convincing that the company now plans a clinical "proof of concept study" (short study with a limited number of patients). MM is a form of blood cancer starting in plasma cells in the bone marrow and, similar to skeletal metastases in prostate cancer (CRPC), causes breakdown of bone. MM is an incurable cancer for which a number of different drugs are used to slow down the disease. Patients eventually become resistant to existing drugs, that often have severe side effects. ODX's unique mechanism of action, together with very mild side effects, makes the drug a strong candidate for treatment of MM as well. The company believes that, given MM's market size and ODX's clear potential for the disease, it is of the higher priority to obtain supplementary clinical data.